Bcl-2
- CAS No.
- Chemical Name:
- Bcl-2
- Synonyms
- bfl1;Bcl-2;bcl2l5;Anti-ACC-1;Anti-ACC-2;Anti-BCL2L5;bfl-1 protein;Bcl-2 Active human;B-cell CLL/lymphoma 2;BCL2, GST tagged human
- CBNumber:
- CB6946557
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MFCD00239644
- MOL File:
- Mol file
| storage temp. | -20°C |
|---|---|
| NCI Dictionary of Cancer Terms | BCL2 |
| FDA UNII | 8RQM3E2NEV |
Bcl-2 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SAB2501619 | Anti-BCL2A1 antibody produced in goat affinity isolated antibody, buffered aqueous solution | 100μG | $568 | 2024-03-01 | Buy | |
| Sigma-Aldrich | AV09047 | Anti-BCL2A1 antibody produced in rabbit affinity isolated antibody | 100μL | $524 | 2024-03-01 | Buy | |
| Sigma-Aldrich | SAB1306719 | ANTI-BCL-2 (CENTER SER70) antibody produced in rabbit affinity isolated antibody, buffered aqueous solution | 400μL | $461 | 2023-01-07 | Buy | |
| Sigma-Aldrich | SAB1306605 | ANTI-PHOSPHO-BCL-2(S70) antibody produced in rabbit affinity isolated antibody, buffered aqueous solution | 400μL | $461 | 2023-01-07 | Buy | |
| Sigma-Aldrich | SAB1305613 | ANTI-PHOSPHO-BCL-2(T56) antibody produced in rabbit affinity isolated antibody, buffered aqueous solution | 400μL | $461 | 2023-01-07 | Buy |
Bcl-2 Chemical Properties,Uses,Production
Pharmacology
BCL-2 has been characterized in SCLC via immunohistochemistry, microarray detection of mRNA, genomic sequencing and proteomic profiling with levels up to 84%. In preclinical models, BCL-2 binds and sequesters BH3-only proapoptotic proteins BID or BIM and prevents them from interacting with the pore-forming effectors that lead to apoptosis and cell death. Understanding of the mechanism of BCL-2 proteins has led to two approaches to inhibiting this pathway, either by direct inhibition of BCL-2 or using BH-3 mimetics. ABT-263, a BH3 mimetic, demonstrated antitumor activity in laboratory models of SCLC but unfortunately has not led to repeated success in the clinic. Phase II trials of ABT-263 have not demonstrated success. Out of 26 patients, only 1 showed a response to treatment with ABT-263. Venetoclax, an effective BCL-2 inhibitor which has been effective clinically in treating a variety of hematologic malignancies, has also been investigated. Preclinical data appears promising as venetoclax, dosed at 100?mg/kg/qd, induced tumor regression in mouse models, and further investigation is required.
Bcl-2 Preparation Products And Raw materials
Raw materials
Preparation Products
Bcl-2 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Yaji Biological Technology Co., Ltd. | 021-34661275 15301693058 | yajikit@163.com | China | 8345 | 58 |
| Shanghai Huzhen Industrial Co., LTD | 021-60345367 13916550749 | sales@shzbio.com | China | 9965 | 58 |
| Beijing Boorsen Biotechnology Co., Ltd | 400-901-9800 18611424007 | cis@bioss.com.cn | China | 9518 | 58 |
| United States Biological | -- | sales@advtechind.com | United States | 6106 | 58 |